SG11201805092WA - Cortistatin analogs and uses thereof - Google Patents

Cortistatin analogs and uses thereof

Info

Publication number
SG11201805092WA
SG11201805092WA SG11201805092WA SG11201805092WA SG11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA SG 11201805092W A SG11201805092W A SG 11201805092WA
Authority
SG
Singapore
Prior art keywords
international
mpk
quincy
president
cambridge
Prior art date
Application number
SG11201805092WA
Other languages
English (en)
Inventor
Matthew Shair
Henry Pelish
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of SG11201805092WA publication Critical patent/SG11201805092WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201805092WA 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof SG11201805092WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387246P 2015-12-23 2015-12-23
US201662297494P 2016-02-19 2016-02-19
PCT/US2016/068125 WO2017112815A1 (en) 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof

Publications (1)

Publication Number Publication Date
SG11201805092WA true SG11201805092WA (en) 2018-07-30

Family

ID=59091204

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805092WA SG11201805092WA (en) 2015-12-23 2016-12-21 Cortistatin analogs and uses thereof

Country Status (17)

Country Link
US (1) US20180298024A1 (he)
EP (1) EP3394072A4 (he)
JP (1) JP2019508368A (he)
KR (1) KR20180095051A (he)
CN (1) CN108699085A (he)
AU (1) AU2016377678A1 (he)
BR (1) BR112018012647A2 (he)
CA (1) CA3009324A1 (he)
CL (1) CL2018001733A1 (he)
CO (1) CO2018007535A2 (he)
EA (1) EA201891511A1 (he)
IL (1) IL260123A (he)
MX (1) MX2018007804A (he)
PH (1) PH12018501351A1 (he)
RU (1) RU2018126984A (he)
SG (1) SG11201805092WA (he)
WO (1) WO2017112815A1 (he)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016287581B2 (en) 2015-07-02 2019-06-06 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ. ホフマン-ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
KR20210118812A (ko) * 2018-11-01 2021-10-01 사이로스 파마수티컬스, 인크. 시클린-의존성 키나제 7 (cdk7)의 억제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723689C (en) * 2008-05-05 2016-07-05 Ryan A. Shenvi Synthesis of (+) cortistatin a and related compounds
US20110190323A1 (en) * 2008-08-28 2011-08-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses thereof
US20130217014A1 (en) * 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) * 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
EP3505521A1 (en) * 2013-12-24 2019-07-03 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof

Also Published As

Publication number Publication date
CA3009324A1 (en) 2017-06-29
CO2018007535A2 (es) 2018-07-31
IL260123A (he) 2018-07-31
EA201891511A1 (ru) 2018-12-28
PH12018501351A1 (en) 2019-02-27
KR20180095051A (ko) 2018-08-24
AU2016377678A1 (en) 2018-07-12
CL2018001733A1 (es) 2018-11-09
RU2018126984A (ru) 2020-01-23
US20180298024A1 (en) 2018-10-18
CN108699085A (zh) 2018-10-23
EP3394072A4 (en) 2019-05-29
MX2018007804A (es) 2019-07-04
BR112018012647A2 (pt) 2018-12-04
EP3394072A1 (en) 2018-10-31
JP2019508368A (ja) 2019-03-28
WO2017112815A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805092WA (en) Cortistatin analogs and uses thereof
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201804363UA (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201407793TA (en) Compounds and compositions for modulating egfr activity
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201805001UA (en) Method of treating influenza a